Compare ConocoPhillips (COP) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs DexCom, Inc. — how do they compare? ConocoPhillips trades at $133.54 (market cap $155.98B), while DexCom, Inc. trades at $84.38 (market cap $31.81B). The key difference: ConocoPhillips is far larger — about 4.9× DexCom, Inc.'s market cap, and ConocoPhillips pays a 2.59% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and DexCom, Inc. for 62 Days on average.
| COP | DXCM | |
|---|---|---|
Market Cap | $155.98B | $31.81B |
Volume | 4,774,951 | 2,861,821 |
Sector | Energy | Health |
52-Week High | $141.22 | $92.34 |
52-Week Low | $85.66 | $54.84 |
Typical Hold Time | 79 Days | 62 Days |
Enterprise Value | $171.58B | $31.26B |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $129.84, up 0.38% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a net income margin of 14.65% and a P/E of 17.17, while recent earnings beat expectations in Q1 and Q2 2026. A 20-year LNG supply deal with Venture Global, announced October 1, 2026, highlights strategic growth initiatives.
The outlook is positive, supported by a 75% analyst buy rating and a consensus price target of $154.75, implying 19% upside. Risks include geopolitical exposure in the Middle East and oil price volatility, but robust cash flow and shareholder returns provide stability for investors.
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
